Search Results
ESMO 2020 Highlights on 1st line durvalumab and tremelimumab for mPDAC: The PA.7 study
ESMO 2020 Highlights on pembrolizumab as 1st line therapy for aUC: The KEYNOTE-361 study
ESMO 2020 Highlights on nivolumab+cabozantinib as 1st line therapy for aRCC: The CheckMate 9ER study
ESMO 2020 Highlights on 1st line lorlatinib for ALK+ NSCLC: The CROWN Study
ESMO 2020 Highlights on neoadjuvant ICI in early TNBC: The IMpassion031 study
ESMO Daily Reporter: Immunotherapy in solid tumours: Early phase trials leading to novel approaches
ESMO 2020 Highlights on lenvatinib plus pembrolizumab in advanced solid tumours: LEAP-005
Highlights from ESMO 2020
DANUBE trial: Durvalumab alone or with tremelimumab for metastatic bladder cancer
ESMO 2020 Highlights on neoadjuvant mFOLFIRINOX for T3-4 rectal cancer: The PRODIGE 23 study
DUTRENEO: durvalumab and tremelimumab vs chemo
ESMO 2020 Highlights on blocking PI3K/AKT signalling pathway in mCRPC: The IPATential150 study
